Cigarette smoking prevails even among type 2 diabetes patients and is a major cause of adverse cardiac events. The two main way-outs followed are behavioral counseling and smoking cessation medications. A study was designed to evaluate the efficacy and safety of one such drug, namely varenicline in patients with type 2 diabetes. This ‘ Journal Watch ’ summarizes this study titled “Efficacy and Safety of Varenicline for Smoking Cessation in Patients with Type 2 Diabetes,” published in JAMA Network Open, 2022 .
What was the need for the study? The studies conducted on effective smoking cessation interventions in diabetic patients are limited. The behavioral and metabolic characteristics of smokers with type 2 diabetes vary from person to person which further necessitates a randomized clinical trial of the smoking cessation drug varenicline. This particular drug was chosen because…
